IL158552A0 - Lipids containing omega-3 fatty acids - Google Patents
Lipids containing omega-3 fatty acidsInfo
- Publication number
- IL158552A0 IL158552A0 IL15855203A IL15855203A IL158552A0 IL 158552 A0 IL158552 A0 IL 158552A0 IL 15855203 A IL15855203 A IL 15855203A IL 15855203 A IL15855203 A IL 15855203A IL 158552 A0 IL158552 A0 IL 158552A0
- Authority
- IL
- Israel
- Prior art keywords
- fatty acids
- lipids containing
- containing omega
- omega
- lipids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15855203A IL158552A0 (en) | 2003-10-22 | 2003-10-22 | Lipids containing omega-3 fatty acids |
CN2013102535938A CN103381172A (zh) | 2003-10-22 | 2004-10-21 | 含ω-3和ω-6脂肪酸的甘油磷脂 |
CNA200480038107XA CN1897955A (zh) | 2003-10-22 | 2004-10-21 | 含ω-3和ω-6脂肪酸的甘油磷脂 |
JP2006536258A JP2007509131A (ja) | 2003-10-22 | 2004-10-21 | オメガ−3およびオメガ−6脂肪酸を含有するグリセロリン脂質 |
EP10180547.1A EP2258377B1 (en) | 2003-10-22 | 2004-10-21 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
PCT/IL2004/000957 WO2005037848A2 (en) | 2003-10-22 | 2004-10-21 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
KR1020127022875A KR20120115419A (ko) | 2003-10-22 | 2004-10-21 | 오메가-3 및 오메가-6 지방산을 함유하는 글리세로인지질 |
RU2006116267/15A RU2362566C2 (ru) | 2003-10-22 | 2004-10-21 | Липиды, содержащие жирные кислоты омега-3 и омега-6 |
BRPI0415744A BRPI0415744B8 (pt) | 2003-10-22 | 2004-10-21 | uso de uma preparação lipídica contendo ácidos graxos ômega-3 e ômega-6, esta preparação, uso de glicerofosfolipídios, composição nutracêutica e artigo alimentar funcional |
CA2542504A CA2542504C (en) | 2003-10-22 | 2004-10-21 | Lipids containing omega-3 and omega-6 fatty acids |
EP04791827A EP1689413A2 (en) | 2003-10-22 | 2004-10-21 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
AU2004282006A AU2004282006C1 (en) | 2003-10-22 | 2004-10-21 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
KR1020067007683A KR101331658B1 (ko) | 2003-10-22 | 2004-10-21 | 오메가-3 및 오메가-6 지방산을 함유하는 글리세로인지질 |
US10/994,175 US20050130937A1 (en) | 2003-10-22 | 2004-11-19 | Lipids containing omega-3 and omega-6 fatty acids |
IL174925A IL174925A (en) | 2003-10-22 | 2006-04-11 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
US11/414,150 US8052992B2 (en) | 2003-10-22 | 2006-04-28 | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
US11/872,258 US20080085319A1 (en) | 2003-10-22 | 2007-10-15 | Lipids containing omega-3 and omega-6 fatty acids |
US11/872,440 US7968112B2 (en) | 2003-10-22 | 2007-10-15 | Lipids containing omega-3 and omega-6 fatty acids |
US12/215,080 US7935365B2 (en) | 2003-10-22 | 2008-06-24 | Glycerophospholipids for the improvement of cognitive functions |
US12/590,893 US8470345B2 (en) | 2003-10-22 | 2009-11-16 | Lipids containing omega-3 and omega-6 fatty acids |
JP2012141384A JP5835671B2 (ja) | 2003-10-22 | 2012-06-06 | オメガ−3おおびオメガ−6脂肪酸を含有するグリセロリン脂質 |
IL224977A IL224977A (en) | 2003-10-22 | 2013-02-28 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15855203A IL158552A0 (en) | 2003-10-22 | 2003-10-22 | Lipids containing omega-3 fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158552A0 true IL158552A0 (en) | 2004-05-12 |
Family
ID=34044222
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15855203A IL158552A0 (en) | 2003-10-22 | 2003-10-22 | Lipids containing omega-3 fatty acids |
IL174925A IL174925A (en) | 2003-10-22 | 2006-04-11 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
IL224977A IL224977A (en) | 2003-10-22 | 2013-02-28 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL174925A IL174925A (en) | 2003-10-22 | 2006-04-11 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
IL224977A IL224977A (en) | 2003-10-22 | 2013-02-28 | Glycerophospholipids containing omega-3 and omega-6 fatty acids |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP2258377B1 (xx) |
JP (2) | JP2007509131A (xx) |
KR (2) | KR20120115419A (xx) |
CN (2) | CN1897955A (xx) |
AU (1) | AU2004282006C1 (xx) |
BR (1) | BRPI0415744B8 (xx) |
CA (1) | CA2542504C (xx) |
IL (3) | IL158552A0 (xx) |
RU (1) | RU2362566C2 (xx) |
WO (1) | WO2005037848A2 (xx) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
US7935365B2 (en) * | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
IL158552A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Lipids containing omega-3 fatty acids |
IL158553A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Method for preparing phosphatidylserine containing omega-3 acid moieties |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP5697293B2 (ja) * | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
RU2008138380A (ru) * | 2006-02-28 | 2010-04-10 | Бристол-Маерс Сквибб Компани (Us) | Использование dha и ara для получения композиции, предназначенной для регуляции экспрессии генов |
JP2008260743A (ja) * | 2006-08-03 | 2008-10-30 | Nagase Chemtex Corp | Nqo1発現増強剤 |
JPWO2008081989A1 (ja) | 2006-12-28 | 2010-04-30 | サントリーホールディングス株式会社 | 神経再生剤 |
EP2612672A1 (en) | 2007-03-28 | 2013-07-10 | Aker BioMarine AS | Bioeffective krill oil compositions |
US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
CN103202353A (zh) * | 2007-11-01 | 2013-07-17 | 恩兹默泰克有限公司 | 用于婴儿营养的脂质混合物 |
US9085527B2 (en) | 2008-07-08 | 2015-07-21 | Catabasis Pharmaceuticals, Inc. | Fatty acid acylated salicylates and their uses |
US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
US20130295171A1 (en) | 2009-07-23 | 2013-11-07 | U.S NUTRACEUTICALS, LLC d/b/a Valensa International | Krill oil and reacted astaxanthin composition and associated method |
RU2642653C2 (ru) | 2009-10-29 | 2018-01-25 | Акасти Фарма, Инк. | Концентрированные терапевтические фосфолипидные композиции |
EP2493296B1 (en) | 2009-10-30 | 2019-01-09 | Retrotope, Inc. | Alleviating oxidative stress disorders with pufa derivatives |
JP5778185B2 (ja) * | 2010-02-11 | 2015-09-16 | カトリーケ・ウニベルシタイト・リユーベン | リン脂質プロファイリング及びガン |
WO2011137160A2 (en) * | 2010-04-30 | 2011-11-03 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans |
US8663704B2 (en) | 2010-04-30 | 2014-03-04 | U.S. Nutraceuticals, LLC | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans |
US9763897B2 (en) | 2010-04-30 | 2017-09-19 | U.S. Nutraceuticals, LLC | Therapeutic astaxanthin and phospholipid composition and associated method |
RU2467334C2 (ru) * | 2010-08-24 | 2012-11-20 | Федеральное государственное бюджетное учреждение "Дальневосточный научный центр физиологии и патологии дыхания" Сибирского отделения РАМН | СПОСОБ ОЦЕНКИ МИКРОВЯЗКОСТИ МЕМБРАН ЭРИТРОЦИТОВ ПУТЕМ ВЫЧИСЛЕНИЯ КОЭФФИЦИЕНТА ЭКСИМЕРИЗАЦИИ ПИРЕНА Кэкс У БЕРЕМЕННЫХ, ПЕРЕНЕСШИХ ОБОСТРЕНИЕ ГЕРПЕС-ВИРУСНОЙ ИНФЕКЦИИ В ТРЕТЬЕМ ТРИМЕСТРЕ ГЕСТАЦИИ, С УЧЕТОМ ОПРЕДЕЛЕНИЯ ПРОЦЕНТНОГО СОДЕРЖАНИЯ ОЛЕИНОВОЙ КИСЛОТЫ В МЕМБРАНАХ ЭРИТРОЦИТОВ |
GB201016139D0 (en) * | 2010-09-24 | 2010-11-10 | Univ Leuven Kath | Cancer phosholipidome |
CA2834342C (en) | 2011-04-26 | 2021-08-31 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
EP2701698B1 (en) | 2011-04-26 | 2020-12-23 | Retrotope, Inc. | Disorders implicating pufa oxidation |
KR102014524B1 (ko) | 2011-04-26 | 2019-08-26 | 레트로토프 인코포레이티드 | 산화성 망막 질환 |
DK2701695T3 (da) | 2011-04-26 | 2019-06-17 | Retrotope Inc | Neurodegenerative lidelser og muskelsygdomme, der involverer polyumættede fedtsyrer |
WO2013033618A1 (en) | 2011-09-02 | 2013-03-07 | Arctic Nutrition As | Lipid compositions with high dha content |
RU2014139008A (ru) * | 2012-02-29 | 2016-04-20 | Б. Браун Мельзунген Аг | Гормонсодержащая эмульсия, содержащая фосфолипиды криля |
EP2819681A1 (en) * | 2012-03-02 | 2015-01-07 | N.V. Nutricia | Method for improving functional synaptic connectivity |
WO2013136183A2 (en) | 2012-03-12 | 2013-09-19 | Innolipid, As | Oxidixable fatty acid composition delivery form |
WO2014045127A2 (en) | 2012-09-19 | 2014-03-27 | Aker Biomarine As | Omega-3 phospholipid supplements for females |
WO2014140873A2 (en) | 2013-03-14 | 2014-09-18 | Aker Biomarine As | Omega- 3 phospholipid supplements for improved brain maturity |
CN103242407A (zh) * | 2013-05-15 | 2013-08-14 | 张雅茹 | 含多不饱和脂肪酰基的磷脂酰甾醇和/或磷脂酰甾烷醇及制备方法和应用 |
AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
CN103609752B (zh) * | 2013-12-02 | 2016-05-25 | 内蒙古伊利实业集团股份有限公司 | 一种改善脑部认知功能的组合物及其制备方法与应用 |
EP3076978A4 (en) | 2013-12-05 | 2017-08-16 | Enzymotec Ltd. | Serine glycerophospholipid preparation and method for treatment of seizures |
GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
CN106535650A (zh) | 2014-04-30 | 2017-03-22 | 恩兹莫特克有限公司 | 磷虾油制剂和它们的用途 |
SG11201703944XA (en) * | 2014-11-20 | 2017-06-29 | Enzymotec Ltd | Phospholipid preparations for the improvement of communication skills |
KR102515207B1 (ko) | 2015-02-11 | 2023-03-29 | 에이커 바이오마린 앤탁틱 에이에스 | 지질 조성물 |
EP3256003B1 (en) | 2015-02-11 | 2022-11-09 | Aker Biomarine Antarctic AS | Lipid extraction processes |
US10894056B2 (en) * | 2015-07-13 | 2021-01-19 | Enzymotec Ltd | Phospholipid preparations for the improvement of sleep |
EP3380452B1 (en) | 2015-11-23 | 2021-03-24 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
KR101744203B1 (ko) * | 2016-01-12 | 2017-06-20 | (주)노터스생명과학 | 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물 |
EP3426259A4 (en) | 2016-03-10 | 2019-10-09 | Enzymotec Ltd. | PHOSPHOLIPID PREPARATIONS FOR ENHANCING NEUROPLASTICITY |
ES2663392B2 (es) * | 2016-05-17 | 2018-09-24 | Universidad De La Laguna | Complemento nutricional para la protección de neuronas frente al riesgo de Alzheimer y Parkinson en mujeres combinando isoflavonas y ácido docosahexaenoico. |
MX2019003285A (es) * | 2016-09-29 | 2019-11-11 | Soc Des Produits Nestle S A Star | Acidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia. |
CN109793802A (zh) * | 2017-11-16 | 2019-05-24 | 西双版纳华坤生物科技有限责任公司 | 一种用于预防和治疗帕金森症的物质及制备方法和用途 |
KR102406690B1 (ko) * | 2018-01-31 | 2022-06-07 | 킨지루시 가부시키 가이샤 | 인식기능 향상제 |
WO2019156210A1 (ja) | 2018-02-09 | 2019-08-15 | 日本水産株式会社 | リンパ循環改善剤 |
CN108721269A (zh) * | 2018-07-10 | 2018-11-02 | 广东海洋大学 | 一种epa与dha混合剂在防治焦虑和快感缺乏方面的应用 |
AU2021224854A1 (en) | 2020-02-21 | 2022-10-06 | Biojiva Llc | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
JPWO2022050355A1 (xx) * | 2020-09-04 | 2022-03-10 | ||
CN113749255B (zh) * | 2021-09-15 | 2022-11-29 | 江南大学 | 一种磷脂组合物在修复肌肉损伤的应用 |
GR20220100576A (el) * | 2022-07-13 | 2024-02-09 | Σταυρουλα Κωνσταντινου Μπασακιδου | Βρωσιμα ελαια εμπλουτισμενα με θρεπτικα συστατικα για την ενισχυση της λειτουργιας του εγκεφαλου |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54117034A (en) * | 1978-02-28 | 1979-09-11 | Nippon Shoji Kk | Treating agent for consciousness and perception motion disorder |
JP2524217B2 (ja) * | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
JPH0279311A (ja) * | 1988-09-14 | 1990-03-19 | Ngk Insulators Ltd | 電気設備の高電圧瑞末部における接地層先端部の電界緩和構造及びその形成方法 |
JPH03188088A (ja) * | 1989-12-15 | 1991-08-16 | Ajinomoto Co Inc | 新規リゾホスファチジルセリン |
JPH0717855A (ja) * | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
GB9301629D0 (en) * | 1993-01-27 | 1993-03-17 | Scotia Holdings Plc | Formulations containing unsaturated fatty acids |
JP3467794B2 (ja) * | 1993-03-09 | 2003-11-17 | 日本油脂株式会社 | 学習能向上剤 |
JPH06279311A (ja) * | 1993-03-26 | 1994-10-04 | Sagami Chem Res Center | プロテインキナーゼcアイソザイムの活性化剤 |
US5925669A (en) * | 1994-03-22 | 1999-07-20 | Molecular/Structural Bio Technologies, Inc. | Carrier compositions for anti-neoplastic drugs |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
WO1997039759A2 (en) * | 1996-04-24 | 1997-10-30 | Brigham And Women's Hospital | Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder |
US6344482B1 (en) * | 1997-04-23 | 2002-02-05 | Andrew L. Stoll | Omega-3 fatty acids in the treatment of bipolar disorder |
FR2762993B1 (fr) * | 1997-05-06 | 1999-08-13 | Inst Rech Biolog Sa | Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique |
AU2003297573A1 (en) * | 2002-11-27 | 2004-06-23 | Cedric Francois | Compositions and methods for treating transplants |
IL158552A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Lipids containing omega-3 fatty acids |
-
2003
- 2003-10-22 IL IL15855203A patent/IL158552A0/xx unknown
-
2004
- 2004-10-21 AU AU2004282006A patent/AU2004282006C1/en active Active
- 2004-10-21 JP JP2006536258A patent/JP2007509131A/ja active Pending
- 2004-10-21 KR KR1020127022875A patent/KR20120115419A/ko not_active Application Discontinuation
- 2004-10-21 WO PCT/IL2004/000957 patent/WO2005037848A2/en active Application Filing
- 2004-10-21 BR BRPI0415744A patent/BRPI0415744B8/pt active IP Right Grant
- 2004-10-21 RU RU2006116267/15A patent/RU2362566C2/ru active
- 2004-10-21 EP EP10180547.1A patent/EP2258377B1/en active Active
- 2004-10-21 CN CNA200480038107XA patent/CN1897955A/zh active Pending
- 2004-10-21 KR KR1020067007683A patent/KR101331658B1/ko active IP Right Grant
- 2004-10-21 CN CN2013102535938A patent/CN103381172A/zh active Pending
- 2004-10-21 CA CA2542504A patent/CA2542504C/en not_active Expired - Fee Related
- 2004-10-21 EP EP04791827A patent/EP1689413A2/en not_active Withdrawn
-
2006
- 2006-04-11 IL IL174925A patent/IL174925A/en active IP Right Grant
-
2012
- 2012-06-06 JP JP2012141384A patent/JP5835671B2/ja active Active
-
2013
- 2013-02-28 IL IL224977A patent/IL224977A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP2012211168A (ja) | 2012-11-01 |
EP2258377B1 (en) | 2019-08-28 |
JP2007509131A (ja) | 2007-04-12 |
BRPI0415744B1 (pt) | 2018-07-17 |
IL174925A (en) | 2014-01-30 |
IL174925A0 (en) | 2008-02-09 |
RU2006116267A (ru) | 2007-12-10 |
KR20120115419A (ko) | 2012-10-17 |
RU2362566C2 (ru) | 2009-07-27 |
AU2004282006C1 (en) | 2010-10-21 |
IL224977A (en) | 2014-09-30 |
KR101331658B1 (ko) | 2013-11-20 |
KR20060094526A (ko) | 2006-08-29 |
EP2258377A2 (en) | 2010-12-08 |
BRPI0415744A (pt) | 2006-12-19 |
CA2542504C (en) | 2014-01-07 |
CA2542504A1 (en) | 2005-04-28 |
WO2005037848A2 (en) | 2005-04-28 |
BRPI0415744B8 (pt) | 2021-05-25 |
CN1897955A (zh) | 2007-01-17 |
EP1689413A2 (en) | 2006-08-16 |
WO2005037848A3 (en) | 2005-05-26 |
CN103381172A (zh) | 2013-11-06 |
AU2004282006A1 (en) | 2005-04-28 |
EP2258377A3 (en) | 2011-10-05 |
JP5835671B2 (ja) | 2015-12-24 |
AU2004282006B2 (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL158552A0 (en) | Lipids containing omega-3 fatty acids | |
PL1755565T3 (pl) | Miękka kapsułka żelatynowa zawierająca wielonienasycony kwas tłuszczowy omega-3 | |
HK1132433A1 (en) | Nutritional supplement containing long-chain polyunsaturated fatty acids | |
HK1105871A1 (en) | Composition containing statins and omega-3 fatty acids | |
AU2003281542A8 (en) | Preparation of microbial oil containing polyunsaturated fatty acids | |
HK1102348A1 (en) | Composition containing polyglycerol/medium-chain fatty acid ester | |
EP1685218A4 (en) | Fatty acid esters and their use | |
IL172847A0 (en) | Method for the production of multiply-unsaturated fatty acids in transgenic organisms | |
IL210233A0 (en) | Omega 3 fatty acid formulations | |
EP1753298A4 (en) | STABILIZATION FOR THE OXIDATION OF OMEGA-3 FATTY ACIDS IN CACAOHUTE BUTTER CONTAINING LITTLE LINOLEIC ACID | |
IL172617A0 (en) | Biaryloxymethylarene-carboxylic acids | |
EP1620543A4 (en) | PRODUCTION OF POLYUNSATURATED FATTY ACIDS IN OLEAGINOUS YEAST | |
PL377614A1 (pl) | Kompozycje zawierające kwasy tłuszczowe i aminokwasy | |
GB0016452D0 (en) | Vitamin K and essential fatty acids | |
EP1937704A4 (en) | ELONGASE OF C16 / 18 FATTY ACIDS FROM MORTIERELLA ALPINA | |
AU2003217759A8 (en) | Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression | |
EP1858352A4 (en) | COMPOSITION COMPRISING A POWDER CONTAINING POLYUNSATURATED LONG-CHAIN ESTERIFIED FATTY ACIDS AND MICROENCAPSULES DISTRIBUTED IN AN EFFERVESCENT BASE | |
PL1656449T3 (pl) | Desaturazy kwasów tłuszczowych z Primula | |
EP1710296A4 (en) | LIPIDIC COMPOSITION CONTAINING A PHOSPHOLIPID AND A COMPOUND SUPPLYING LONG-CHAIN POLYUNSATURATED FATTY ACIDS, AND FOOD CONTAINING THE SAME | |
GB2405874B (en) | Fatty acid ester slip agents for polyethylene terephthalate | |
AU2003208769A8 (en) | Methods for the production of unsaturated fatty acids | |
EP1617830A4 (en) | ESTERIFIED FATTY ACID COMPOSITION | |
AU2003296701A8 (en) | Nematode fatty acid desaturase-like sequences | |
AU2003241207A1 (en) | Process for preparing functional beverage with omega-3 fatty acids | |
NO20022578D0 (no) | Fosfolipider inneholdende omega-3 fettsyrer |